Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for vTv Therapeutics (VTVT) over the last 12 years, with Q3 2025 value amounting to $98.5 million.

  • vTv Therapeutics' Cash & Equivalents rose 13678.85% to $98.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $98.5 million, marking a year-over-year increase of 13678.85%. This contributed to the annual value of $36.7 million for FY2024, which is 28901.12% up from last year.
  • Per vTv Therapeutics' latest filing, its Cash & Equivalents stood at $98.5 million for Q3 2025, which was up 13678.85% from $25.9 million recorded in Q2 2025.
  • vTv Therapeutics' 5-year Cash & Equivalents high stood at $98.5 million for Q3 2025, and its period low was $8.2 million during Q3 2023.
  • Its 5-year average for Cash & Equivalents is $25.8 million, with a median of $17.9 million in 2022.
  • Per our database at Business Quant, vTv Therapeutics' Cash & Equivalents surged by 97279.69% in 2021 and then tumbled by 4629.38% in 2023.
  • Over the past 5 years, vTv Therapeutics' Cash & Equivalents (Quarter) stood at $13.4 million in 2021, then fell by 9.61% to $12.1 million in 2022, then dropped by 22.1% to $9.4 million in 2023, then skyrocketed by 289.01% to $36.7 million in 2024, then soared by 168.07% to $98.5 million in 2025.
  • Its last three reported values are $98.5 million in Q3 2025, $25.9 million for Q2 2025, and $31.1 million during Q1 2025.